Compare Citius Pharmaceuticals Inc (CTXR) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Motorola Solutions Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Motorola Solutions Inc trades at $421.22 (market cap $68.67B). The key difference: Motorola Solutions Inc is far larger — about 4690.6× Citius Pharmaceuticals Inc's market cap, and Motorola Solutions Inc pays a 1.17% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MSI | |
|---|---|---|
Market Cap | $14.64M | $68.67B |
Sector | Health | Technology |
52-Week High | $1.82 | $490.30 |
52-Week Low | $0.53 | $363.83 |
Enterprise Value | $10.86M | $77.38B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Motorola Solutions (MSI) trades at $418.06, down 1.14% today, with a neutral technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $11.68B and net income of $2.15B, supported by a 99.88% ROE. Recent developments include the $1.5B D-Fend acquisition and AI expansion for emergency response systems, positioning MSI for growth in public safety technology.
MSI presents a compelling investment case with analyst consensus price target of $512.33 (22.5% upside) and 71% buy ratings. Strong profitability and strategic AI investments are offset by high valuation multiples (P/E 33.71) and negative cash flow from significant acquisitions. Key risks include integration challenges from recent deals and competitive pressure in the public safety sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
